NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- H1 , on a mission to connect the world with the right doctors, today announced several key milestones: H1 is strengthening its leadership team with the appointment of former FDA Commissioner Dr. Stephen M. Hahn to its board; announcing the strategic acquisition of Ribbon Health ; and unveiling a series of innovative products.“H1 continues to live its mission by connecting the world with the right doctors,” said Ariel Katz , co-founder and CEO of H1. “By adding Dr. Hahn, with his deep expertise and impressive credentials, to our leadership team and expanding our portfolio through the development of new products and the acquisition of Ribbon Health, we’re confident we have everything in place to accomplish that mission.”Former FDA Commissioner Joins H1 Board of DirectorsAs part of its continued growth, H1 has welcomed Dr

What You Should Know:– H1, on a mission to connect the world to the right doctors, today announced a strategic partnership with CTI Clinical Trial & Consulting Services (CTI), a leading global full-spectrum research service provider.– Through this partnership, CTI will leverage H1’s Trial Landscape platform to drive data-informed clinical trial planning and execution to enhance strategic feasibility, real-world evidence, and clinical trial execution on a global scale. This integration bolsters efficiency and advances diversity, equity, and inclusion (DEI) initiatives in clinical trials, ultimately making research more representative and impactful.CTI and H1 Partner to Enhance Clinical Trial Efficiency and DiversityThe collaboration between CTI Clinical Trial and Consulting Services (CTI) and H1 comes at a pivotal time for Contract Research Organizations (CROs), which face increasing complexity in analyzing diverse datasets across multiple indications and regions. By integrating H1’s Trial Landscape platform, a powerful AI-driven clinical trial data repository, CTI can streamline the analysis of patient demographics and treatment sites worldwide, optimizing study and research site strategies to focus on successful trial execution.A primary objective of this partnership is advancing CTI’s commitment to FDA diversity guidelines. Using H1’s comprehensive data, CTI will craft detailed diversity action plans, identifying trial sites and principal investigators (PIs) with access to underrepresented patient populations. This approach ensures trials generate inclusive, representative data that enhance research quality, safety, and applicability.The Trial Landscape platform supports all phases of the trial lifecycle:Pre-award phase : Facilitates precise identification of sites and patients, a crucial factor in securing trial awards.: Facilitates precise identification of sites and patients, a crucial factor in securing trial awards. Post-award phase: Enhances timely and effective execution, meeting sponsor needs while improving global trial outcomes.Earl Seltzer, Senior Director of Strategy & Innovation at CTI, emphasized the importance of the partnership: “We’re excited to collaborate with H1 and leverage the advanced capabilities of the Trial Landscape platform

In addition to diversity data, H1 has also launched Site Rescue, an AI-powered functionality designed to address the growing complexity of clinical trials.